Q2 2020 Biogaia AB Earnings Call Transcript
Ladies and gentlemen, welcome to the BioGaia second quarter 2020 report. (Operator Instructions) Today, I'm pleased to present Isabelle Ducellier, CEO. Madam, please go ahead.
()-&
Thank you so much. And dear investor, Alex and I wish you welcome to BioGaia Q2 report. I hope you had nice holiday despite the special circumstances I will call it. So from the top line point of view, we have a good quarter, with a total sales increasing by 10%, mainly thanks to the increase of the sales in pediatric. If we look at pediatric product, the main SKU and the main increase comes from our drops.
If we look at the Adult segment, it is driven mainly by Prodentis, or oral health probiotics and by gastric tablet. I will come back to that later. All our 2 regions are showing a growth at different pace with modest 1% for EMEA and a very strong double digit, both for APAC and for Americas.
Next page, please. Obviously, as for Q1, unfortunately
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |